Physician profile
Laura Smith
NPI 1902541998
$2,575.34
in general payments reported to CMS, 2019-2025
14 companies · $1,443 in 2025
The $1,443 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $142 · 2023: $609 · 2024: $381 · 2025: $1,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,413 · Travel and Lodging: $1,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,413.26 |
| Travel and Lodging | $1,019.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,641.72 | 2023-2025 | General - Therapies, Cds Broad Portfolio Offering, Watchman Flx |
| Actelion Pharmaceuticals US, INC. | $271.74 | 2023 | Uptravi, Opsumit |
| Impulse Dynamics (USA) INC. | $119.46 | 2024 | Optimizer |
| Baxter Healthcare | $79.53 | 2022 | |
| Medtronic, INC. | $76.78 | 2024 | Micra |
| Astrazeneca Pharmaceuticals LP | $73.63 | 2023-2024 | Farxiga, Wainua |
| Merck Sharp & Dohme LLC | $69.44 | 2023 | Verquvo |
| Edwards Lifesciences Corporation | $68.98 | 2025 | Sapien 3 Ultra Resilia |
| Pfizer INC. | $62.81 | 2022 | |
| Janssen Pharmaceuticals, INC | $49.68 | 2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $23.95 | 2025 | |
| Abiomed | $23.69 | 2024 | Impella |
| Cardiva Medical, INC. | $13.93 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.